Weekly Recap | EyePoint -8.98%, consensus target far above spotWeekly Review·Sep 19 at 06:03 AMEYPT+3.32%
Weekly Recap | EyePoint -63.93%, Phase 3 trial misses endpointWeekly Review·Aug 22 at 04:55 AMEYPT+3.32%
